Freenome Appoints Rob Guigley as Chief Commercial Officer, Prepares for Commercial Launch of Cancer Tests.

Freenome has appointed industry veteran Rob Guigley as Chief Commercial Officer to drive commercial strategy. The appointment comes as the company's agreement with Exact Sciences clears antitrust review. Guigley will lead the execution of the exclusive U.S. licensing and commercialization of Freenome's colorectal cancer blood-based screening tests and build out the company's core commercial capabilities. The FDA is reviewing the Premarket Approval Application for the initial version of the test, with approval expected in H2 2026.